With the burgeoning interest in innovative treatments for metabolic syndrome and obesity treatment, a head-to-head comparison of the GLP-1/GIP agonist and the dual GIP and GLP-1 receptor agonist has become paramount. While both therapies function through similar mechanisms – modulating glucagon-like peptide-1 and GIP receptors – key distinction